CTU A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

  • Zhang, Alison (Primary Chief Investigator)
  • Contacos, Christine (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Chester, Catherine (Clinical Trial Unit Staff)
  • Martin, Lewis (Clinical Trial Unit Staff)
  • TAIDI, Gina (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleMK-5684-003
AcronymOMAHA-3
StatusActive
Effective start/end date5/02/24 → 18/01/29